Drug intelligence / Profile preview

dibromodulcitol + mitomycin c + vinblastine

Development stage: Unknown
Lead developer: Kyowa Kirin
Modality: Small Molecules
Administration: Oral, Intravenous

Overview

This is a combination chemotherapy regimen consisting of dibromodulcitol, mitomycin C, and vinblastine. Dibromodulcitol is an alkylating agent that interferes with DNA replication and transcription. Mitomycin C is an antitumor antibiotic that acts as a bioreductive alkylating agent, cross-linking DNA and inhibiting DNA synthesis. Vinblastine is a vinca alkaloid that inhibits microtubule formation in the mitotic spindle, arresting cell division at metaphase. The DMV regimen has been studied primarily for advanced breast cancer, showing moderate efficacy with manageable toxicity profiles[1][5].

Other names: DMV chemotherapy

Targets

TUBB (Tubulin (alpha and beta subunits))DNA

Beyond the preview

Go deeper on dibromodulcitol + mitomycin c + vinblastine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on dibromodulcitol + mitomycin c + vinblastine.

Explore the full profile